With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.

Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.

Administration suggests Operation Warp Speed vaccines come with US FDA review speed advantage, but the agency backtracks on that assertion. FDA may need to get creative to ensure it has enough staff to quickly review all vaccines, expert says. 

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.